0000885590-12-000006.txt : 20120124 0000885590-12-000006.hdr.sgml : 20120124 20120124170546 ACCESSION NUMBER: 0000885590-12-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120120 FILED AS OF DATE: 20120124 DATE AS OF CHANGE: 20120124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stolz Brian M. CENTRAL INDEX KEY: 0001524803 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 12542529 MAIL ADDRESS: STREET 1: VALEANT PHARMACEUTICALS INTERNATIONAL,IN STREET 2: 7150 MISSISSAUGA ROAD CITY: MISSISSAUGA STATE: A6 ZIP: L5N 8M5 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7150 MISSISSAUGA ROAD STREET 2: MISSISSAUGA CITY: ONTARIO STATE: A6 ZIP: 00000 BUSINESS PHONE: 905 286-3000 MAIL ADDRESS: STREET 1: 7150 MISSISSAUGA ROAD STREET 2: MISSISSAUGA CITY: ONTARIO STATE: A6 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 primary_doc.xml PRIMARY DOCUMENT X0304 4 2012-01-20 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001524803 Stolz Brian M. VALEANT PHARMACEUTICALS INTERNATIONAL,IN 7150 MISSISSAUGA ROAD MISSISSAUGA A6 L5N8M5 ONTARIO, CANADA 0 1 0 0 EVP, Administration and CHCO Common Stock, no par value 2012-01-20 4 A 0 2400 0 A 15260 D Represents Restricted Share Units received under an employee Share Matching Program ("Matching RSUs") in connection with the officer's purchase of Company common stock. Each Matching RSU represents a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. 1/3 of the Matching RSUs will vest each on the first, second and third anniversary of the date of grant subject to contingent employment and retention of the corresponding purchased shares. This number includes common shares purchased by the officer as well as other outstanding equity awards that were previously reported in Table 1. by: Nicholas Zanoni for Brian Stolz 2012-01-24